{"id":"msb11022","safety":{"commonSideEffects":[{"rate":null,"effect":"Cardiotoxicity / left ventricular dysfunction"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MSB11022 is a proposed biosimilar to trastuzumab (Herceptin), a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2) on cancer cells. By blocking HER2 signaling, it prevents cell proliferation and induces antibody-dependent cellular cytotoxicity (ADCC) in HER2-overexpressing tumors. As a biosimilar, it is designed to have comparable efficacy and safety to the reference trastuzumab product.","oneSentence":"MSB11022 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and inhibiting tumor growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:16.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive breast cancer"},{"name":"HER2-positive gastric cancer"}]},"trialDetails":[{"nctId":"NCT02660580","phase":"PHASE3","title":"MSB11022 in Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2016-02-16","conditions":"Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis","enrollment":443},{"nctId":"NCT04018599","phase":"PHASE1","title":"Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2019-07-15","conditions":"Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis","enrollment":216},{"nctId":"NCT03052322","phase":"PHASE3","title":"MSB11022 in Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2017-01-31","conditions":"Moderate to Severe Rheumatoid Arthritis","enrollment":288},{"nctId":"NCT03014947","phase":"PHASE1","title":"MSB11022 in Healthy Subjects","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2014-05","conditions":"Healthy Subjects","enrollment":237}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adalimumab"],"phase":"phase_3","status":"active","brandName":"MSB11022","genericName":"MSB11022","companyName":"Fresenius Kabi SwissBioSim GmbH","companyId":"fresenius-kabi-swissbiosim-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MSB11022 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and inhibiting tumor growth. Used for HER2-positive breast cancer, HER2-positive gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}